Alpha-galactosidase A - Research Corporation Technologies

Drug Profile

Alpha-galactosidase A - Research Corporation Technologies

Alternative Names: Alpha-galactosidase - Research Corporation Technologies; Arginosuccinate lyase; Beta-glucosidase

Latest Information Update: 27 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Research Corporation Technologies
  • Developer Orphan Medical; Research Corporation Technologies
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fabry's disease

Most Recent Events

  • 27 Nov 1998 Discontinued-Preclinical for Fabry's disease in USA (Unknown route)
  • 13 May 1997 Orphan Medical is a licensee for α-galactosidase in the USA
  • 13 May 1997 Preclinical development for Fabry's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top